Acadian Asset Management
ATHE

Acadian Asset Management’s Alterity Therapeutics ATHE Stock Holding History

Acadian Asset Management’s Portfolio ATHE Stock Details ATHE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6K Sell
1,863
-2,936
-61% -$9.95K ﹤0.01% 1984
2025
Q4 		$14K Hold
4,799
– – ﹤0.01% 1918
2025
Q3 		$18K Buy
+4,799
New +$23.2K ﹤0.01% 1774
2017
Q4 		– Sell
-464
Closed -$13K – 1569
2017
Q3 		$13K Buy
+464
New +$12.6K ﹤0.01% 1257

Other funds holding ATHE

TLCM
Twin Lakes Capital Management Redwood Shores, California $220M AUM 31.75% 1-Year Est. Return
HWM
HB Wealth Management Atlanta, Georgia $15.5B AUM 18.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GT
Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Acadian Asset Management's ATHE Position: Q1 2026 in Review

Acadian Asset Management reduced its Alterity Therapeutics (ATHE) stake by 61% in Q1 2026, selling an estimated $9.95K and leaving 1,863 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #1984.

Acadian Asset Management first reported a position in ATHE in Q3 2017 and has held it in 4 quarters since. The position peaked at $18K in Q3 2025. 15 funds tracked by Wall St. Rank hold ATHE as of Q1 2026.

  • Acadian Asset Management held 1,863 shares of Alterity Therapeutics worth $6K as of Q1 2026.
  • Acadian Asset Management sold 2,936 Alterity Therapeutics shares in Q1 2026, an estimated $9.95K.
  • Alterity Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q1 2026, its #1984 holding.
  • Acadian Asset Management first reported a position in Alterity Therapeutics in Q3 2017 and has held it in 4 quarters since.
  • Acadian Asset Management's Alterity Therapeutics position peaked at $18K in Q3 2025.
  • 15 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q1 2026.

Based on Acadian Asset Management's 13F filing for Q1 2026, filed 13 May 2026.